Transcranial Direct Current Stimulation on Inhibitory Control in Addictions.
Substance-Related Disorders
About this trial
This is an interventional treatment trial for Substance-Related Disorders focused on measuring substance abuse, transcraneal electrical stimulation, tDCS, inhibitory control, drug craving, treatment adherence
Eligibility Criteria
Inclusion Criteria:
- Substance abuse
- Under clinical treatment at the Noesso Addiction Rehabilitation Center La Quinta, Laujar de Andarax, Spain
- Participation approved by the clinical team
- Participation approved by the experimental team by means of the Göttingen screening questionnaire
- Signed informed consent
- At least 26 points in the Montreal Cognitive Assessment (MOCA) evaluation
Exclusion Criteria:
- Epilepsy or history of epilepsy (convulsions due compsumtion not included)
- Cardiopathy or cardiac electronic devices
- Skin reaction or high sensitivity to tDCS
- Head metallic implant
- Serious mental disease
- Exclusion because of clinical criteria (physician, psychologist)
Sites / Locations
- Psychobiology Lab
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Sham Comparator
Active-Active
Active-Sham
Sham-Active
Sham-Sham
Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h) and in Phase 2 (5 sessions, intersession time-24h).
Participants will receive active-tDCS stimulation (anode F4 / cathode F3) at 2 mA during 20 min in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).
Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and active-tDCS at 2 mA during 20 min in Phase 2 (5 sessions, intersession time-24h).
Participants will receive sham-tDCS stimulation (anode F4 / cathode F3) at 2 mA (active-stimulation lasting for 1 min) in Phase 1 (5 sessions, intersession time-24h), and sham-tDCS at 2 mA (active-stimulation lasting for 1 min) in Phase 2 (5 sessions, intersession time-24h).